Abstract: The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases.

Abstract: Disclosed is a driving apparatus for a display, which drives pixels using a double rate driving (DRD) method. The driving apparatus includes a first latch circuit storing first pixel data, a second latch circuit storing second pixel data, a first selection circuit selecting one of the first pixel data and the second pixel data and outputting selection data, and a second selection circuit selecting one of the selection data of a pair of adjacent first selection units and outputting source data.

Abstract: Disclosed is a system for a display, which drives pixels using a double rate driving (DRD) method. The system includes a timing controller configured to provide a data packet and a lock signal, and a plurality of drivers each configured to restore display data and a clock of the data packet and output a source signal corresponding to the display data using the clock. The lock signal is fed back to the timing controller via the plurality of drivers. Each of the drivers outputs an internal lock signal, obtained by updating the lock signal with information on a restored clock, in next order. Each of the drivers may operate in a low power mode.

Abstract: The present specification relates to a composition containing novel (20S,24R)-6-O-?-D-glucopyranosyl(1?2)-?-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, a pharmaceutically acceptable salt thereof, a hydrate or a solvate thereof as an active ingredient. The composition exhibits an excellent exercise ability enhancing effect and anti-fatigue effect.

Abstract: The present specification relates to a composition containing novel ginsenoside, (20S,24R)-6-O-?-D-glucopyranosyl(1?2)-?-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, a pharmaceutically acceptable salt thereof, a hydrate or a solvate thereof as an active ingredient. The composition exhibits excellent effects in glycemic control, lipid metabolic control, cholesterol control, anti-obesity and blood circulation improvement.

Abstract: The present disclosure relates to a composition comprising (20S,24R)-6-O-?-D-glucopyranosyl(1?2)-?-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, which is a novel ginsenoside, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof as an active ingredient. In addition, it relates to a method for preventing or improving menopausal symptoms, which comprises administering an effective amount of (20S,24R)-6-O-?-D-glucopyranosyl(1?2)-?-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof to a subject in need thereof. The novel ginsenoside has a superior effect of preventing or improving menopausal symptoms with a low risk of breast cancer.

Abstract: The present disclosure relates to a composition comprising (20S,24R)-6-O-?-D-glucopyranosyl(1?2)-?-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, which is a novel ginsenoside, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof as an active ingredient. In addition, it relates to a method for improving skin elasticity or skin wrinkles, which comprises administering an effective amount of (20S,24R)-6-O-?-D-glucopyranosyl(1?2)-?-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof to a subject in need thereof. The novel ginsenoside, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof has a superior effect of improving skin elasticity and skin wrinkles.

Abstract: The present invention relates to a composition for, inter alia, preventing or treating a climacteric disease, or preventing or improving a climacteric skin symptom comprising a soybean extract comprising coumestrol as an active ingredient, and more specifically relates to a composition for, inter alia, preventing or treating a climacteric disease, or preventing or improving a climacteric skin symptom comprising a germinated and fermented soybean extract comprising coumestrol as an active ingredient.

Abstract: Embodiments of the present disclosure relate to a display driving device and a display device including the same. The display driving device includes a source driving circuit configured to convert image data of respective channels into source signals; a polarity control circuit configured to receive polarity data for the respective channels, and generate a polarity control signal for controlling polarities of the source signals depending on a logic combination of the polarity data; and a multiplexer circuit configured to output the source signals to data lines in response to the polarity control signal.

Abstract: The present specification relates to a composition containing a tea extract with an increased specific ingredient content for prevention or alleviation of lipid metabolism disorders. The use of a preparation method and a composition according to the present specification can effectively prevent and treat lipid metabolism disorders including obesity without side effects, thereby meeting related demands and promoting the development of corresponding industries.

Abstract: The present disclosure discloses a display device that performs a read operation corresponding to a touch based on a multipoint interface (MPI) protocol. In the display device, a microcontroller and a plurality of drivers share MPI buses and perform the read operation for a touch, and turning on of reception buffers may be efficiently controlled by providing a wake-up signal by a selected driver designated by a read command of the microcontroller to unselected drivers at the time of completion of transmission of touch data.

Abstract: The present specification relates to a composition containing novel (20S,24R)-6-O-?-D-glucopyranosyl(1?2)-?-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, a pharmaceutically acceptable salt thereof, a hydrate or a solvate thereof as an active ingredient. The composition exhibits an excellent skin brightening effect.

Abstract: Provided is a display device that transmits and receives data on the basis of a MPI protocol. The display device includes a microcontroller, source drivers, and first and second MPI buses, wherein the microcontroller and the source drivers perform bi-directional communication on the basis of the MPI protocol in which transmission types for occupying the first and second MPI buses are set.

Abstract: The present specification relates to a composition containing novel (20S,24R)-6-O-?-D-glucopyranosyl(1->2)-?-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, a pharmaceutically acceptable salt thereof, a hydrate or a solvate thereof as an active ingredient. The composition exhibits an excellent exercise ability enhancing effect and anti-fatigue effect.

Abstract: The present specification relates to a composition containing novel (20S,24R)-6-O-?-D-glucopyranosyl(1?2)-?-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, a pharmaceutically acceptable salt thereof, a hydrate or a solvate thereof as an active ingredient. The composition exhibits an excellent skin brightening effect.

Abstract: The present specification relates to a composition containing novel ginsenoside, (20S,24R)-6-O-?-D-glucopyranosyl(1->2)-?-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, a pharmaceutically acceptable salt thereof, a hydrate or a solvate thereof as an active ingredient. The composition exhibits excellent effects in glycemic control, lipid metabolic control, cholesterol control, anti-obesity and blood circulation improvement.

Abstract: Embodiments of the present disclosure relate to a display driving device and a display device including the same. The display driving device includes a source driving circuit configured to convert image data of respective channels into source signals; a polarity control circuit configured to receive polarity data for the respective channels, and generate a polarity control signal for controlling polarities of the source signals depending on a logic combination of the polarity data; and a multiplexer circuit configured to output the source signals to data lines in response to the polarity control signal.

Abstract: The present disclosure discloses a display device that performs a read operation corresponding to a touch based on a multipoint interface (MPI) protocol. In the display device, a microcontroller and a plurality of drivers share MPI buses and perform the read operation for a touch, and turning on of reception buffers may be efficiently controlled by providing a wake-up signal by a selected driver designated by a read command of the microcontroller to unselected drivers at the time of completion of transmission of touch data.

Abstract: Provided is a display device that transmits and receives data on the basis of a MPI protocol. The display device includes a microcontroller, source drivers, and first and second MPI buses, wherein the microcontroller and the source drivers perform bi-directional communication on the basis of the MPI protocol in which transmission types for occupying the first and second MPI buses are set.

Abstract: The present invention relates to a composition for, inter alia, preventing or treating a climacteric disease, or preventing or improving a climacteric skin symptom comprising a soybean extract comprising coumestrol as an active ingredient, and more specifically relates to a composition for, inter alia, preventing or treating a climacteric disease, or preventing or improving a climacteric skin symptom comprising a germinated and fermented soybean extract comprising coumestrol as an active ingredient.